Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure
Background Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (C...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 1999-10, Vol.138 (4), p.625-632 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 632 |
|---|---|
| container_issue | 4 |
| container_start_page | 625 |
| container_title | The American heart journal |
| container_volume | 138 |
| creator | Vesely, David L. Dietz, John R. Parks, James R. Antwi, Ernest A. Overton, Rose M. McCormick, Michael T. Cintron, Guillermo Schocken, Douglas D. |
| description | Background Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF).
Methods and Results LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (
P < .001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (
P < .01), which was still significantly (
P < .01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (
P < .05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF.
Conclusions These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals. (Am Heart J 1999;138:625-32.) |
| doi_str_mv | 10.1016/S0002-8703(99)70175-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70782923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870399701754</els_id><sourcerecordid>70782923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-2e1ce1f9c75227d02ea7f3c849460b3ab61939259c26282430f6acef219d56553</originalsourceid><addsrcrecordid>eNqFkM9rFDEUx0NR7Lb6J1RyEGkPoy-ZmWRyElnaKhQ8qOeQzby0kZlkmmQX_O_NdhftzdPjwef7fnwIuWDwgQETH78DAG8GCe2lUlcSmOyb7oSsGCjZCNl1L8jqL3JKznL-VVvBB_GKnDLogXMQKzKv47yY5HMMNDq6w5xxoqOfTImJmjDSKYb7xtjiwz0NpiS_TVi8pQsuxY9IfaDlAWlJaMqMoezH2JrBXPwO6QOaVKgzfqq51-SlM1PGN8d6Tn7eXP9Yf2nuvt1-XX--a2yroDQcmUXmlJU953IEjka61g6d6gRsWrMRTLWK98ry-hDvWnDCWHScqbEXfd-ek_eHuUuKj9t6iZ59tjhNJmDcZi1BDlzxtoL9AbQp5pzQ6SX52aTfmoHee9ZPnvVeolZKP3nWXc29PS7YbmYcn6UOYivw7giYbM3kkgnW53-ckgOAqtinA4bVxs5j0tl6DBZHn9AWPUb_n0v-ALtpmnk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70782923</pqid></control><display><type>article</type><title>Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Vesely, David L. ; Dietz, John R. ; Parks, James R. ; Antwi, Ernest A. ; Overton, Rose M. ; McCormick, Michael T. ; Cintron, Guillermo ; Schocken, Douglas D.</creator><creatorcontrib>Vesely, David L. ; Dietz, John R. ; Parks, James R. ; Antwi, Ernest A. ; Overton, Rose M. ; McCormick, Michael T. ; Cintron, Guillermo ; Schocken, Douglas D.</creatorcontrib><description>Background Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF).
Methods and Results LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (
P < .001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (
P < .01), which was still significantly (
P < .01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (
P < .05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF.
Conclusions These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals. (Am Heart J 1999;138:625-32.)</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/S0002-8703(99)70175-4</identifier><identifier>PMID: 10502206</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Atrial Natriuretic Factor - administration & dosage ; Atrial Natriuretic Factor - therapeutic use ; Biological and medical sciences ; Cardiovascular system ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Humans ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Natriuresis - drug effects ; Osmolar Concentration ; Peptide Fragments - administration & dosage ; Peptide Fragments - therapeutic use ; Pharmacology. Drug treatments ; Protein Precursors - administration & dosage ; Protein Precursors - therapeutic use ; Time Factors ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>The American heart journal, 1999-10, Vol.138 (4), p.625-632</ispartof><rights>1999 Mosby, Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-2e1ce1f9c75227d02ea7f3c849460b3ab61939259c26282430f6acef219d56553</citedby><cites>FETCH-LOGICAL-c390t-2e1ce1f9c75227d02ea7f3c849460b3ab61939259c26282430f6acef219d56553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-8703(99)70175-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1978009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10502206$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vesely, David L.</creatorcontrib><creatorcontrib>Dietz, John R.</creatorcontrib><creatorcontrib>Parks, James R.</creatorcontrib><creatorcontrib>Antwi, Ernest A.</creatorcontrib><creatorcontrib>Overton, Rose M.</creatorcontrib><creatorcontrib>McCormick, Michael T.</creatorcontrib><creatorcontrib>Cintron, Guillermo</creatorcontrib><creatorcontrib>Schocken, Douglas D.</creatorcontrib><title>Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF).
Methods and Results LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (
P < .001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (
P < .01), which was still significantly (
P < .01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (
P < .05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF.
Conclusions These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals. (Am Heart J 1999;138:625-32.)</description><subject>Atrial Natriuretic Factor - administration & dosage</subject><subject>Atrial Natriuretic Factor - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Natriuresis - drug effects</subject><subject>Osmolar Concentration</subject><subject>Peptide Fragments - administration & dosage</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Precursors - administration & dosage</subject><subject>Protein Precursors - therapeutic use</subject><subject>Time Factors</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9rFDEUx0NR7Lb6J1RyEGkPoy-ZmWRyElnaKhQ8qOeQzby0kZlkmmQX_O_NdhftzdPjwef7fnwIuWDwgQETH78DAG8GCe2lUlcSmOyb7oSsGCjZCNl1L8jqL3JKznL-VVvBB_GKnDLogXMQKzKv47yY5HMMNDq6w5xxoqOfTImJmjDSKYb7xtjiwz0NpiS_TVi8pQsuxY9IfaDlAWlJaMqMoezH2JrBXPwO6QOaVKgzfqq51-SlM1PGN8d6Tn7eXP9Yf2nuvt1-XX--a2yroDQcmUXmlJU953IEjka61g6d6gRsWrMRTLWK98ry-hDvWnDCWHScqbEXfd-ek_eHuUuKj9t6iZ59tjhNJmDcZi1BDlzxtoL9AbQp5pzQ6SX52aTfmoHee9ZPnvVeolZKP3nWXc29PS7YbmYcn6UOYivw7giYbM3kkgnW53-ckgOAqtinA4bVxs5j0tl6DBZHn9AWPUb_n0v-ALtpmnk</recordid><startdate>19991001</startdate><enddate>19991001</enddate><creator>Vesely, David L.</creator><creator>Dietz, John R.</creator><creator>Parks, James R.</creator><creator>Antwi, Ernest A.</creator><creator>Overton, Rose M.</creator><creator>McCormick, Michael T.</creator><creator>Cintron, Guillermo</creator><creator>Schocken, Douglas D.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991001</creationdate><title>Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure</title><author>Vesely, David L. ; Dietz, John R. ; Parks, James R. ; Antwi, Ernest A. ; Overton, Rose M. ; McCormick, Michael T. ; Cintron, Guillermo ; Schocken, Douglas D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-2e1ce1f9c75227d02ea7f3c849460b3ab61939259c26282430f6acef219d56553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Atrial Natriuretic Factor - administration & dosage</topic><topic>Atrial Natriuretic Factor - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Natriuresis - drug effects</topic><topic>Osmolar Concentration</topic><topic>Peptide Fragments - administration & dosage</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Precursors - administration & dosage</topic><topic>Protein Precursors - therapeutic use</topic><topic>Time Factors</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vesely, David L.</creatorcontrib><creatorcontrib>Dietz, John R.</creatorcontrib><creatorcontrib>Parks, James R.</creatorcontrib><creatorcontrib>Antwi, Ernest A.</creatorcontrib><creatorcontrib>Overton, Rose M.</creatorcontrib><creatorcontrib>McCormick, Michael T.</creatorcontrib><creatorcontrib>Cintron, Guillermo</creatorcontrib><creatorcontrib>Schocken, Douglas D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vesely, David L.</au><au>Dietz, John R.</au><au>Parks, James R.</au><au>Antwi, Ernest A.</au><au>Overton, Rose M.</au><au>McCormick, Michael T.</au><au>Cintron, Guillermo</au><au>Schocken, Douglas D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>1999-10-01</date><risdate>1999</risdate><volume>138</volume><issue>4</issue><spage>625</spage><epage>632</epage><pages>625-632</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF).
Methods and Results LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (
P < .001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (
P < .01), which was still significantly (
P < .01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (
P < .05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF.
Conclusions These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals. (Am Heart J 1999;138:625-32.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>10502206</pmid><doi>10.1016/S0002-8703(99)70175-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 1999-10, Vol.138 (4), p.625-632 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70782923 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Atrial Natriuretic Factor - administration & dosage Atrial Natriuretic Factor - therapeutic use Biological and medical sciences Cardiovascular system Heart Failure - drug therapy Heart Failure - physiopathology Humans Infusions, Intravenous Male Medical sciences Middle Aged Natriuresis - drug effects Osmolar Concentration Peptide Fragments - administration & dosage Peptide Fragments - therapeutic use Pharmacology. Drug treatments Protein Precursors - administration & dosage Protein Precursors - therapeutic use Time Factors Vasodilator agents. Cerebral vasodilators |
| title | Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T21%3A27%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20vessel%20dilator%20and%20long-acting%20natriuretic%20peptide%20in%20the%20treatment%20of%20congestive%20heart%20failure&rft.jtitle=The%20American%20heart%20journal&rft.au=Vesely,%20David%20L.&rft.date=1999-10-01&rft.volume=138&rft.issue=4&rft.spage=625&rft.epage=632&rft.pages=625-632&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/S0002-8703(99)70175-4&rft_dat=%3Cproquest_cross%3E70782923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70782923&rft_id=info:pmid/10502206&rft_els_id=S0002870399701754&rfr_iscdi=true |